Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976293 | 0.84 | ALDH1A1 (0.36) | F10LMNAPOLBALDH1A1ATM | |
| SCHEMBL12164497 | 0.84 | ALDH1A1 (0.36) | F10LMNAPOLBALDH1A1ATM | |
| SCHEMBL3429780 | 0.84 | ALDH1A1 (0.36) | F10LMNAPOLBALDH1A1ATM | |
| SCHEMBL9611225 | 0.84 | ALDH1A1 (0.36) | F10LMNAPOLBALDH1A1ATM | |
| SCHEMBL15985998 | 0.79 | POLB (0.35) | LMNAPOLBALDH1A1ATMHSD17B10 | |
| SCHEMBL11512064 | 0.79 | POLB (0.35) | LMNAPOLBALDH1A1ATMHSD17B10 | |
| SCHEMBL10941440 | 0.79 | CYP3A4 (0.33) | LMNAPOLBALDH1A1 | |
| SCHEMBL16843474 | 0.79 | CYP3A4 (0.33) | LMNAPOLBALDH1A1 | |
| SCHEMBL7359163 | 0.76 | POLB (0.33) | LMNAPOLBALDH1A1ATMHSD17B10 | |
| SCHEMBL9313180 | 0.76 | F10 (0.40) | F10LMNAPOLBALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-4466072-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | Almac Discovery Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| CN-118946566-A | Heterocyclic compounds as ubiquitin-specific protease 7 inhibitors | 阿尔麦克探索有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2023139241-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, SENP7 | F10 4244/4885LMNA 3424/4885POLB 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.